Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...

Q4 2025 earnings call recap: revenue, procedure growth, 2026 guidance, margin drivers & risks from sales changes—read now.

Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

PROCEPT BioRobotics (NASDAQ:PRCT) reported fourth-quarter 2025 results that were marked by strong U.S. procedure growth but lower-than-expected consumable revenue, as management implemented changes to ...

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by ...

PROCEPT BioRobotics Corp. PRCT shares are down during Thursday’s premarket session following the company’s recent financial results and updates on its revenue guidance. Performance Metrics In its ...

Despite a strong demand and strategic restructuring, PROCEPT BioRobotics Corp faces short-term disruptions and financial setbacks.

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive ...

Ratings for PROCEPT BioRobotics (NASDAQ:PRCT) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...

Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...